Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Epilepsy; Paediatric Partial Onset Seizures
View Full LandscapeTarget Indication
Epilepsy; Paediatric Partial Onset Seizures
Clinical Trial
NCT00566254Last updated: 12/23/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Zonisamide Viatris (previously Zonisamide Mylan)
Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
View on EMAZonegran
Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
View on EMA